ID   F-36P
AC   CVCL_2037
SY   F36P
DR   CLO; CLO_0051549
DR   AddexBio; C0003014/4881
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-7721
DR   ArrayExpress; E-MTAB-7722
DR   BioSample; SAMN03472228
DR   BioSample; SAMN03473531
DR   BioSample; SAMN10989568
DR   cancercelllines; CVCL_2037
DR   Cell_Model_Passport; SIDM01498
DR   Cosmic; 975247
DR   Cosmic; 1012066
DR   Cosmic; 1465955
DR   Cosmic; 2089665
DR   Cosmic; 2306204
DR   DepMap; ACH-000487
DR   DSMZ; ACC-543
DR   DSMZCellDive; ACC-543
DR   ECACC; 99072808
DR   GEO; GSM482505
DR   GEO; GSM887010
DR   GEO; GSM888079
DR   GEO; GSM1374478
DR   GEO; GSM1446734
DR   GEO; GSM2124120
DR   IARC_TP53; 28392
DR   LiGeA; CCLE_670
DR   Lonza; 262
DR   PharmacoDB; F36P_363_2019
DR   Progenetix; CVCL_2037
DR   RCB; RCB0775
DR   TOKU-E; 4108
DR   Wikidata; Q54833036
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=1834251;
RX   PubMed=16408098;
RX   PubMed=22460905;
RX   PubMed=23955599;
RX   PubMed=25984343;
RX   PubMed=26589293;
RX   PubMed=27750403;
RX   PubMed=30285677;
RX   PubMed=30629668;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31160637;
RX   PubMed=31978347;
WW   http://www.cells-talk.com/index.php/page/copelibrary?key=F-36P
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: LL-100 blood cancer cell line panel.
CC   Population: Japanese.
CC   Characteristics: CSF2 or IL3 dependent.
CC   Doubling time: 55 hours (PubMed=25984343); ~24-36 hours (DSMZ=ACC-543).
CC   HLA typing: A*24:02,33:03; B*40:06,58:01; C*03:02,08:01 (PubMed=26589293).
CC   HLA typing: A*24:02:01,33:03:01; B*40:06:01,58:01:01; C*03:02:02,08:01:01; DPA1*01:03:01,01:03:01; DPB1*02:01:02,02:01:02; DQA1*01:02:01,01:02:01; DQB1*04:02:01,06:09:01; DRA*01:02:02,01:02:02; DRB1*08:02:01,13:02:01 (DSMZCellDive=ACC-543).
CC   Sequence variation: Mutation; HGNC; 7132; KMT2A; Simple; p.Glu766Gln (c.2296G>C); Zygosity=Heterozygous (PubMed=27750403; DepMap=ACH-000487).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.376-1G>A (p.Tyr126_Lys132del, c.376_396del21); ClinVar=VCV000481003; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=27750403; DepMap=ACH-000487).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: shRNA library screening.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=1.61%; Native American=0%; East Asian, North=78.68%; East Asian, South=18.21%; South Asian=0%; European, North=0%; European, South=1.5% (PubMed=30894373).
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): AddexBio=C0003014/4881; DSMZ=ACC-543; ECACC=99072808; RCB=RCB0775
ST   Amelogenin: X,Y
ST   CSF1PO: 9
ST   D13S317: 10
ST   D16S539: 10,12
ST   D18S51: 15
ST   D19S433: 12,13
ST   D21S11: 31
ST   D2S1338: 17
ST   D3S1358: 15
ST   D5S818: 13
ST   D7S820: 9,11
ST   D8S1179: 12,15
ST   FGA: 21,24
ST   Penta D: 10,11
ST   Penta E: 16,17
ST   TH01: 8 (AddexBio=C0003014/4881; ECACC=99072808; RCB=RCB0775)
ST   TH01: 8,9 (DSMZ=ACC-543)
ST   TPOX: 9,11
ST   vWA: 14,16
DI   NCIt; C3247; Myelodysplastic syndrome
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   68Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 34
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=1834251; DOI=10.1182/blood.V78.9.2261.2261;
RA   Chiba S., Takaku F., Tange T., Shibuya K., Misawa C., Sasaki K.,
RA   Miyagawa K., Yazaki Y., Hirai H.;
RT   "Establishment and erythroid differentiation of a cytokine-dependent
RT   human leukemic cell line F-36: a parental line requiring
RT   granulocyte-macrophage colony-stimulating factor or interleukin-3, and
RT   a subline requiring erythropoietin.";
RL   Blood 78:2261-2268(1991).
//
RX   PubMed=16408098; DOI=10.1038/sj.leu.2404081;
RA   Quentmeier H., MacLeod R.A.F., Zaborski M., Drexler H.G.;
RT   "JAK2 V617F tyrosine kinase mutation in cell lines derived from
RT   myeloproliferative disorders.";
RL   Leukemia 20:471-476(2006).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=23955599; DOI=10.1038/ng.2731;
RA   Kon A., Shih L.-Y., Minamino M., Sanada M., Shiraishi Y., Nagata Y.,
RA   Yoshida K.-i., Okuno Y., Bando M., Nakato R., Ishikawa S.,
RA   Sato-Otsubo A., Nagae G., Nishimoto A., Haferlach C., Nowak D.,
RA   Sato Y., Alpermann T., Nagasaki M., Shimamura T., Tanaka H., Chiba K.,
RA   Yamamoto R., Yamaguchi T., Otsu M., Obara N., Sakata-Yanagimoto M.,
RA   Nakamaki T., Ishiyama K., Nolte F., Hofmann W.-K., Miyawaki S.,
RA   Chiba S., Mori H., Nakauchi H., Koeffler H.P., Aburatani H.,
RA   Haferlach T., Shirahige K., Miyano S., Ogawa S.;
RT   "Recurrent mutations in multiple components of the cohesin complex in
RT   myeloid neoplasms.";
RL   Nat. Genet. 45:1232-1237(2013).
//
RX   PubMed=25984343; DOI=10.1038/sdata.2014.35;
RA   Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S.,
RA   East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H.,
RA   Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M.,
RA   Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S.,
RA   Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D.,
RA   Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C.,
RA   Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P.,
RA   Golub T.R., Root D.E., Hahn W.C.;
RT   "Parallel genome-scale loss of function screens in 216 cancer cell
RT   lines for the identification of context-specific genetic
RT   dependencies.";
RL   Sci. Data 1:140035-140035(2014).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27750403; DOI=10.1002/gcc.22430;
RA   Palau A., Mallo M., Palomo L., Rodriguez-Hernandez I., Diesch J.,
RA   Campos D., Granada I., Junca J., Drexler H.G., Sole F., Buschbeck M.;
RT   "Immunophenotypic, cytogenetic, and mutational characterization of
RT   cell lines derived from myelodysplastic syndrome patients after
RT   progression to acute myeloid leukemia.";
RL   Genes Chromosomes Cancer 56:243-252(2017).
//
RX   PubMed=30285677; DOI=10.1186/s12885-018-4840-5;
RA   Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X.,
RA   Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H.,
RA   Koeffler H.P.;
RT   "Profiling the B/T cell receptor repertoire of lymphocyte derived cell
RT   lines.";
RL   BMC Cancer 18:940.1-940.13(2018).
//
RX   PubMed=30629668; DOI=10.1371/journal.pone.0210404;
RA   Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.;
RT   "Screening human cell lines for viral infections applying RNA-Seq data
RT   analysis.";
RL   PLoS ONE 14:E0210404-E0210404(2019).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31160637; DOI=10.1038/s41598-019-44491-x;
RA   Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M.,
RA   MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.;
RT   "The LL-100 panel: 100 cell lines for blood cancer studies.";
RL   Sci. Rep. 9:8218-8218(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//